Female liver transplant recipients with the same GFR as male recipients have lower MELD scores - A systematic bias

被引:149
作者
Cholongitas, E.
Marelli, L.
Kerry, A.
Goodier, D. W.
Nair, D.
Thomas, M.
Patch, D.
Burroughs, A. K.
机构
[1] Royal Free Hosp, Liver Transplantat & Hepatobiliary Med Unit, London NW3 2QG, England
[2] Royal Free Hosp, Dept Clin Biochem, London NW3 2QG, England
关键词
creatinine; gender; GFR; liver transplantation; MELD score;
D O I
10.1111/j.1600-6143.2007.01666.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Women have lower glomerular filtration (GFR) than men for the same serum creatinine (Cr) value, not accounted for in model for end-stage liver disease (MELD). We compare male/female Cr, GFR (using MDRD formula) and respective MELD scores in 403 Cr measurements using standard (sCr), O'Leary modified (mCr) and Compensated (cCr) Jaffe and Enzymatic (eCr) in 158 liver disease patients, mCr in 208 liver transplantation (LT) candidates, and EDTA-Cr-51-GFR in 38 other candidates for LT; considering each female as male, a 'corrected' Cr was derived. MELD scores were calculated for measured and 'corrected' Cr in females. Median Cr and GFR in females were lower than males (p < 0.05). Both MDRD and EDTA-Cr-51 GFR were lower in females than males, despite lower Cr values. In females, each MELD score was lower than the corresponding MELD-corrected Cr (p < 0.001) with >= three-point difference in liver disease patients: 25% [sCr]; 23% [mCr]; 11% [eCr]; and 14% [cCr]. In 65% of female LT candidates, two- or three-point difference was found. Females with liver disease have lower GFR than males for the same Cr value; correcting Cr increases MELD score by two or three points in 65% of female LT candidates. MELD score adjustment in females would ensure equal LT priority by gender.
引用
收藏
页码:685 / 692
页数:8
相关论文
共 34 条
[1]  
Arjal R, 2005, HEPATOLOGY, V42, p205A
[2]  
BALIGA P, 1992, SURGERY, V112, P704
[3]   Systematic review: the model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? [J].
Cholongitas, E ;
Papatheodoridis, GV ;
Vangeli, M ;
Terreni, N ;
Patch, D ;
Burroughs, AK .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (11-12) :1079-1089
[4]  
CHOLONGITAS E, 2006, IN PRESS LIVER TRNSP
[5]   Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? [J].
Christensen, E .
JOURNAL OF HEPATOLOGY, 2004, 41 (02) :344-350
[6]   A prognostic model for patients with end-stage liver disease [J].
Cooper, GS ;
Bellamy, P ;
Dawson, NV ;
Desbiens, N ;
Fulkerson, WJ ;
Goldman, L ;
Quinn, LM ;
Speroff, T ;
Landefeld, CS .
GASTROENTEROLOGY, 1997, 113 (04) :1278-1288
[7]   Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis [J].
Dharnidharka, VR ;
Kwon, C ;
Stevens, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (02) :221-226
[8]   Screening for renal disease using serum creatinine: who are we missing? [J].
Duncan, L ;
Heathcote, J ;
Djurdjev, O ;
Levin, A .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (05) :1042-1046
[9]   Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD [J].
Durand, F ;
Valla, D .
JOURNAL OF HEPATOLOGY, 2005, 42 :S100-S107
[10]   Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation [J].
Fraley, DS ;
Burr, R ;
Bernardini, J ;
Angus, D ;
Kramer, DJ ;
Johnson, JP .
KIDNEY INTERNATIONAL, 1998, 54 (02) :518-524